India's richest club sees nine new entrants; Ambani still No 1

Half of the nation’s 100 richest saw gains rising a collective 14% to $517.5 billion, says Forbes. The Covid-19 pandemic may have hit India hard, but nine newcomers joined the ranks of......

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.......

BJP's election loss could bring focus back to reforms

Economists say Modi should rein in 'hotheads' and shift narrative back to jobs and growth, rues Arup Roychoudhury The Bharatiya Janata Party-led alliance’s loss in the Bihar elections might......

Roche's patent pain to be Biocon's gain

Indian firm to soon launch copycat of anti-breast-cancer drug For Swiss pharma major Roche, not pursuing an Indian patent for its anti-breast-cancer drug, Herceptin, might mean a loss of millions......